^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Sitoiganap (ERC1671)

    i
    Company:
    Epitopoietic Research Corp
    Drug class:
    Immunostimulant
    Related drugs:
    Apply
    ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme (NCT01903330)
    Phase 2
    Epitopoietic Research Corporation
    Active, not recruiting
    Last update posted :
    05/16/2022
    Initiation :
    03/01/2014
    Primary completion :
    03/01/2023
    Completion :
    03/01/2023
    IL6 • IL2RA • CD4 • IL10 • CSF2
    |
    Avastin (bevacizumab) • cyclophosphamide • Mvasi (bevacizumab-awwb) • Zirabev (bevacizumab-bvzr) • Sitoiganap (ERC1671) • Leukine (sargramostim) • cyclophosphamide intravenous
    ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab (NCT05366062)
    Phase 2
    Epitopoietic Research Corporation
    Not yet recruiting
    Last update posted :
    05/13/2022
    Initiation :
    07/01/2022
    Primary completion :
    07/31/2025
    Completion :
    07/31/2026
    CD4
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • temozolomide • cyclophosphamide • Sitoiganap (ERC1671)